HTGC · Categories · Offerings
HTGC - Public offerings
Hercules Capital Inc. (HTGC) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for HTGC
- Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029Notes due 2029 Initially Assigned Ratings of Baa2 by Moody’s Investors Service and BBB- by Fitch Ratings, Inc. Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has closed an upsized underwritten public offering of $400.0 million in aggregate principal amount of 6.700% notes due October 2029 (the "Notes"). The Notes are unsecured and bear interest at a rate of 6.700% per year, payable semiannually, will mature on October 8, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company’s option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proceeds from t
- Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has priced an underwritten public offering of $400.0 million in aggregate principal amount of 6.70% notes due October 2029 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on October 8, 2026.The Notes are unsecured and bear interest at a rate of 6.70% per year, payable semiannually and will mature on October 8, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company’s option at par, plus a "make whole" premium, if applicable.The Company expects to use
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031Notes due 2031 Initially Assigned Ratings of Baa2 by Moody’s Investors Service and a BBB- by Fitch Ratings, Inc. Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the "Notes"). The Notes are unsecured and bear interest at a rate of 6.300% per year, payable semiannually, will mature on July 24, 2031, and may be redeemed in whole or in part at any time or from time to time at the Company’s option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proceeds from this offeri
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on July 24, 2026. The Notes are unsecured and bear interest at a rate of 6.300% per year, payable semiannually and will mature on July 24, 2031 and may be redeemed in whole or in part at any time or from time to time at the Company’s option at par, plus a "make whole" premium, if applicable. The Company expects to us
- enGene Reports First Quarter 2026 Financial Results and Provides Business UpdateLEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene planned for 2H 2026 Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028 Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter en
- Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029Notes due 2029 Initially Assigned Ratings of Baa2 by Moody's Investors Service and a BBB- by Fitch Ratings, Inc. Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed an underwritten public offering of $300.0 million in aggregate principal amount of 5.350% notes due February 2029 (the "Notes"). The Notes are unsecured and bear interest at a rate of 5.350% per year, payable semiannually, will mature on February 10, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proceeds from this offering (i) to fund
- Hercules Capital Prices Institutional Notes Offering of $300.0 Million 5.350% Notes due 2029Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" "Hercules Capital," or the "Company"), today announced that it has priced an underwritten public offering of $300.0 million in aggregate principal amount of 5.350% notes due February 2029 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on February 10, 2026. The Notes are unsecured and bear interest at a rate of 5.350% per year, payable semiannually and will mature on February 10, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company ex
- Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRDFDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD) Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted i
- Hercules Capital Closes Upsized Institutional Notes Offering of $350.0 Million 6.000% Unsecured Notes due 2030Notes due 2030 Initially Assigned a Baa3 by Moody's Investors Service and a BBB- by Fitch Ratings, Inc. Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the "Notes"). The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually, will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company intends to use the net proceeds from the offering of the Notes to repay
- Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has priced an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on June 16, 2025. The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually and will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net pro
- Hercules Capital, Inc. Prices Upsized Public Offering of Common StockHercules Capital, Inc. (NYSE:HTGC) ("Hercules") today announced that it has priced its upsized public offering of 6,500,000 shares of its common stock. Hercules has also granted the underwriters an option to purchase up to an additional 975,000 shares of its common stock. The offering is subject to customary closing conditions and is expected to close on August 10, 2023. Morgan Stanley, UBS Investment Bank and Wells Fargo Securities are acting as joint lead book-running managers, Goldman Sachs & Co. LLC, Jefferies and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers, and Compass Point, JMP Securities, a Citizens Company and MUFG are acting as co-manager
- Hercules Capital, Inc. Announces Public Offering of Common StockHercules Capital, Inc. (NYSE:HTGC) ("Hercules") today announced that it plans to make a public offering of 6,000,000 shares of its common stock. Hercules also expects to grant the underwriters for the offering an option to purchase up to an additional 900,000 shares of its common stock. Morgan Stanley, UBS Investment Bank and Wells Fargo Securities are acting as joint lead book-running managers, Goldman Sachs & Co. LLC, Jefferies and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers, and Compass Point, JMP Securities, a Citizens Company and MUFG are acting as co-managers in this offering. Hercules expects to use the net proceeds from this offering (i)
- Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®RED BANK, N.J., Feb. 2, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the close of the $40 million second tranche under the previously announced term loan facility of up to $125 million with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized financing for companies in life sciences. "Exercising the second tranche of this term loan facility provides the anticipated additional capital to advance the commercial launch of TZIELD® as we c
- Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura's cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Bristol Myers Squibb (NYSE:BMY) and a term loan facility with access to up to $125 million from Hercules Capital, Inc. (NYSE:HTGC). If the term loan is fully drawn, proceeds from these two transa
- X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 MonthsBOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggregate of 50,925,365 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase an aggregate of 50,925,365 shares of common stock, to certain institutional accredited investors in a private investment in public equity (PIPE) financing. X4 anticipates that gross proceeds from the PIPE will be approximately $55 million, before deducting fees to the placement agent and other estimated offer
- Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing transactions. The first is a $25 million equity investment by Pfizer Inc. (NYSE:PFE) at $9.90 per share. The second is a term loan facility providing Akero with access to up to $100 million from
- Hercules Capital Closes Upsized Public Offering of $350.0 Million 3.375% Notes Due 2027Notes due 2027 Initially Assigned a Baa3 and BBB+ by Moody's Investors Service and Kroll Bond Rating Agency, Respectively Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed an underwritten public offering of $350.0 million in aggregate principal amount of 3.375% notes due January 2027 (the "Notes"). The Notes are unsecured and bear interest at a rate of 3.375% per year, payable semiannually and will mature on January 20, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proceeds from this offering (i)
- Hercules Capital Prices Upsized Public Offering of $350.0 Million 3.375% Notes due 2027Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has priced an underwritten public offering of $350.0 million in aggregate principal amount of 3.375% notes due January 2027 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on January 20, 2022. The Notes are unsecured and bear interest at a rate of 3.375% per year, payable semiannually and will mature on January 20, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proc
- BiomX Reports Third Quarter 2021 Financial Results and Provides Business UpdateAnnounces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022 Cash Runway Now Extended to End of 2023, Well Beyond Key 2022 Data Readouts FDA Clears BiomX to Begin Phase 1b/2a Trial in Cystic Fibrosis; Trial to Start Imminently Company Will Host a Conference Call and Webcast Today at 8:00 am ET BRANFORD, Conn. and NESS ZIONA, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, reported today financial results and provided a business u
- Hercules Capital Reports Third Quarter 2021 Financial ResultsRecord Q3 Total Gross Debt and Equity Commitments of $719.6 Million Record Q3 Total Gross Fundings of $431.1 Million Record Year-to-Date Total Gross Debt and Equity Commitments of $1.69 Billion Record Year-to-Date Total Gross Fundings of $1.07 Billion Record Undistributed Earnings Spillover of $181.7 Million, or $1.57(1) per Ending Shares Outstanding Increased the Company's Quarterly Base Cash Distribution to $0.33 per Share Closed Public Offering of $325.0 Million 2.625% Notes due 2026 Q3 2021 Financial Achievements and Highlights Net Investment Income "NII" of $38.1 million, or $0.33 per share Total Investment Income of $70.2 million Record total gross new debt and equity com
- Hercules Capital Delivers a New Record by Surpassing $1.5 Billion of Annual Gross Debt and Equity CommitmentsHercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it, together with external funds managed by its adviser subsidiary, have originated more than $1.5 billion year-to-date in annual total gross debt and equity commitments, breaking its previous one-year record of $1.47 billion. "This record-breaking achievement is a testament to the quality of our team and the market-leading position the Hercules platform has established over its 17-year history," said
- Hercules Capital Closes Public Offering of $325.0 Million 2.625% Notes due 2026Notes due 2026 Initially Assigned a Baa3 and BBB+ by Moody's Investors Service and Kroll Bond Rating Agency, Respectively Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 2.625% notes due 2026 (the "Notes"). The Notes are unsecured and bear interest at a rate of 2.625% per year, payable semiannually and will mature on September 16, 2026 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proceeds from this offering (i) to rep
- Hercules Capital Prices Public Offering of $325.0 Million 2.625% Notes Due 2026Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 2.625% notes due September 2026 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on September 16, 2021. The Notes are unsecured and bear interest at a rate of 2.625% per year, payable semiannually and will mature on September 16, 2026 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the ne
- Hercules Capital Reports Second Quarter 2021 Financial ResultsRecord Year-to-Date Total Debt and Equity Commitments of $971.7 Million Record Year-to-Date Total Fundings of $634.0 Million Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception Q2 2021 Net Asset Value per Share Increased 3.1% to $11.71 from Q1 2021 Record Undistributed Earnings Spillover of $160.2 Million, or $1.38(1) per Ending Shares Outstanding Q2 2021 Financial Achievements and Highlights Net Investment Income "NII" of $37.0 million, or $0.32 per share, an increase of 3.6% year-over-year Total Investment Income of $69.6 million, an increase of 2.3% year-over-year Total gross new debt and equity commitments of $440.8 million Net Hercules' debt and e
- AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update– U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for Planned Pivotal Phase 3 TiNivo-2 Study of FOTIVDA in Combination with OPDIVO® (nivolumab); Study Anticipated to Commence Mid-2021 – – Phase 2 Open Label Randomized Study Results of Ficlatuzumab in HNSCC to be Presented at ASCO; Phase 3 Decision Anticipated Mid-2021 – – Company to Host Conference Call Today at 4:30 p.m. ET
- Hercules Capital Reports First Quarter 2021 Financial ResultsRecord Q1 Gross New Debt and Equity Commitments of $530.9 Million Q1 2021 Net Asset Value "NAV" per Share Increased 0.9% to $11.36 from Q4 2020 Strong Available Liquidity of $550.0 Million Record Undistributed Earnings Spillover of $109.1 Million, or $0.94(1) per Ending Shares Outstanding Declared a $0.28 Supplemental Distribution for Fiscal 2021 Payable over Four Quarters beginning with Q1 2021 Q1 2021 Financial Achievements and Highlights Net Investment Income "NII" of $34.6 million, or $0.30 per share Total Investment Income of $68.8 million Total gross new debt and equity commitments of $530.9 million Net Hercules' debt and equity commitments of $467.2 million(2) Total
- Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial ResultsPALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments